New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme ...

There's only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer's VLA15 – and it has just moved another step closer to being available.

Valneva has met its revenue growth target for ... Being developed in collaboration with Pfizer, the candidate is currently the only vaccine programme in clinical development against Lyme disease.